Lanhao Biotech Secures Tens of Millions of Yuan in Series A Funding to Accelerate Registration and Commercialization of Oral Regenerative and Aesthetic Products

VCBeat recently learned that Lan Hao Bio, an emerging player in dental regenerative repair materials and medical aesthetics, has successfully completed a Series A financing round worth tens of millions of yuan on the occasion of its third anniversary. The investment was jointly made by Milestone Ventures and Qingdao High-Tech Venture Capital. The funds will be primarily used for clinical trials, regulatory registration and approval, initial sales and marketing promotion, and the construction of R&D centers for Lan Hao Bio’s dental regenerative repair and medical aesthetics projects.

Lanhao Biotech was established on August 29, 2019. The company is positioned in the fields of oral regenerative repair and medical aesthetics products, with a focus on developing six Class III medical device products. Currently, two of these products are about to be submitted to the National Medical Products Administration (NMPA) for registration approval.

Chen Defu, Founder of BlueHao BioIt stated that Lanhao Biotechnology has focused on the domestically scarce fields of regenerative medicine products and technologies, achieving multiple breakthroughs after years of technical research and development. Particularly in the field of oral regeneration and repair, which is nearly monopolized by imported products, several products developed by Lanhao Biotechnology, such as dental bone powder, have reached international advanced levels.

Dental bone graft materials are classified as high-end dental consumables, primarily used for the regenerative repair of alveolar and maxillofacial bones. The domestic market has long been monopolized by imported products, with domestically produced alternatives holding only a small market share. A key factor contributing to this situation is that previous domestic products lagged in technical performance, failing to adequately meet clinical demands.

Lanhao Biologics’ independently developed dental bone graft powder features superior manufacturing processes and quality performance that is no inferior to imported products, giving it a strong competitive edge. Once regulatory approval is obtained, the product will rapidly enter the market, replacing imports and benefiting domestic patients. In the current economic climate, where the Chinese government encourages domestic circulation, Lanhao Biologics’ dental bone graft powder is poised to substitute imported products, mitigating the risk of supply chain constraints imposed by foreign manufacturers (“chokehold” risks) and helping to alleviate the high cost of dental care for the general public.

Head of Investment, Qingdao High-Tech Venture Capital“The biomedical industry is a key sector that our Qingdao High-Tech Zone prioritizes for support and development. We are particularly optimistic about LanHao Bio’s product portfolio in the fields of dentistry and medical aesthetics. We believe that LanHao Bio will achieve rapid growth and stand out among the many regenerative medicine companies in China.”

Relevant Person in Charge at Milestone VenturesHe stated that oral regenerative repair represents a vast, high-potential, and rapidly growing market. Currently, 85% of the domestic dental bone powder market is monopolized by foreign products, placing domestically produced alternatives at a competitive disadvantage. With 22 years of experience in the bone repair materials industry, Chen Defu has led or participated in the development of multiple domestically produced regenerative medicine products that have been widely adopted in clinical practice. He looks forward to Lan Hao Biology benefiting a broad population of patients and consumers in the future.